Oncology Therapeutic Expertise

Through innovative and proven technologies, alongside our intuitive, seamless workflows, MERIT’s experienced staff bring more than a decade of clinical endpoint expertise, ensuring the success and integrity of your clinical trials.
MERIT Team Experience
Our team’s collective Phase I – Phase III experience includes support for:
  • 500+ oncology studies worldwide
  • 25+ different cancer indications
  • 144+ global clinical trial sites
  • 1,700+ enrolled patients
These studies utilize a variety of advanced imaging modalities.
MERIT Benefits
MERIT brings value to your studies:
  • Technology empowers innovative imaging workflows
  • Clinical operations ensure timely deliverables
  • Proven & experienced medical experts act as an extension of your team
  • QA provides consistent study design & management
Our established workflows reduce risks and costs to complete studies on time by focusing on:
6. Data Security & Privacy 5. Established Regulatory & QA 4. Proven SOPs & Workflows 3. Experienced & Tenured Oncology Team 2. Innovative Single Platform, EXCELSIOR 1. Clinical Trial Excellence
1
Clinical Trial Excellence
  • Fast start-up time
  • Reduces risk to bottom line
  • Flexible & responsive
2
Innovative Single Platform, EXCELSIOR
  • One platform for all study data, queries, reporting/tracking, image transfer & analysis
  • Easy adoption of technology
  • Single system prevents data loss and data inconsistencies
  • Cost savings
3
Experienced & Tenured Oncology Team
  • Access to readers worldwide in any required specialty
  • Global expertise
  • Training, routine monitoring, SOP documentation
4
Proven SOPs & Workflows
  • Step-by-step Imaging Protocols, SOP and Document Support
  • Time-tested protocols and documentation processes
  • Processes and workflows are seamlessly controlled and managed by EXCELSIOR
5
Established Regulatory & QA
  • Indispensable Quality Assurance, Regulatory Support, and Guidance
  • An active partner with sponsors in responding to audits and providing information to regulatory bodies
6
Data Security & Privacy
  • MERIT's systems and processes are standardized and ISO 27001 Certified
  • We prioritize data privacy; MERIT is GDPR, HGRAC, and Data Privacy Framework compliant

Oncology Team Experience

Staff includes:
  • Tenured project managers
  • Dedicated imaging specialists
  • Meticulous quality assurance staff
  • Expert data managers and data quality evaluators
  • Adept software developers
  • Team has managed 500+ oncology studies across 20+ cancer types
  • Our experts have extensive, cumulative experience with RECIST 1.1 and other criteria across all phases of clinical research
  • Highly qualified readers, KOLs, and medical advisor team

Our Readers Have Extensive Knowledge & Training

Our board-certified readers are dedicated academic radiologists, world leaders in their respective fields, and can read a large volume of exams in a timely manner
  • Participated in 1,600+ clinical trials and contributed to 300+ FDA or EMEA marketing authorization filings
  • Trained in RECIST 1.1, iRECIST, mRECIST, Lugano, WHO, RANO, Hallek, PCWG3, Cheson, PERCIST, etc.
  • Reading modalities: MRI, CT, PET, SPECT & X-rays
The Power to Manage Imaging Clinical Trials
All-in-One System provides stakeholder access to curated data.
Sponsors can view study progress and data in a transparent, secure environment.
SINGLE SYSTEM – One validated, secure system containing all study data: images, tasks, queries, site materials, analysis, and read data. Read and Adjudication are performed within the system.
UNIVERSAL – One cloud-based platform bypasses site IT challenges and effectively manages access rights for sites, sponsors, and readers (zero footprint implementation).
TRANSPARENT – Eliminates the question: “Where is our data?” and reduces risk and data delays.
TRUSTED – FDA 510(k) Medical Device.

Recent Case Studies Using EXCELSIOR

Time Savings Gained in Retrospective Study of Glioma

Response Criteria: RANO HGG/LGG
Site Geo: US
Phase: I/IIa
A biotechnology company conducted a partial retrospective review of its early phase study to provide updated and novel data regarding their therapeutic agent in advanced unresectable solid tumors (gliomas). Scans for subjects were evaluated by MERIT readers in a single-reader paradigm. MERIT provided fast, accurate reads to support the company’s quick turnaround times.
Result: Time Savings
30% time reduction from resolving challenges with study start-up, read workflow, and data transfer.

Cost Savings in Newly Diagnosed Glioblastoma Multiforme (GBM) Trial

Response Criteria: RANO
Site Geo: US
Phase: II
A clinical stage biotechnology company launched a Phase II prospective clinical trial in patients with glioblastoma. Mid-study, MERIT was engaged to supply the high-quality imaging data and expertise needed to keep the study on track. MERIT’s robust cloud-based software platform, EXCELSIOR, and our operational experience enabled the project team to handle both retrospective and prospective imaging.
Result: Cost Savings
60% cost reduction associated with early phase Collect & Hold Project

Team Collective Experience Profile

Biliary Tract Cancer
Criteria: RECIST 1.1
Total Studies: 4
Colorectal Cancer
Criteria: RECIST 1.1
Total Studies: 13
Gastric Cancer
Criteria: RECIST 1.1
Total Studies: 7
GI Stromal Tumor
Criteria: RECIST 1.1/depends
Total Studies: 6
Pancreatic Cancer
Criteria: RECIST 1.1
Total Studies: 5
Liver Cancer/Hepatocellular Carcinoma (HCC)
Criteria: RECIST 1.1/depends mRECIST
Total Studies: 15
Melanoma / Skin
Criteria: RECIST 1.1/iRECIST
Total Studies: 19
Brain Cancer / Metastasis
Criteria: RANO/RANO BM
Total Studies: 25
Head & Neck Cancer
Criteria: RECIST 1.1/depends
Total Studies: 17
Thyroid Cancer
Criteria: RECIST 1.1
Total Studies: 6
Multiple Myeloma
Criteria: IMWG2016
Total Studies: 4
Leukemias
Criteria: LUGANO
Total Studies: 5
Lymphomas
Criteria: LUGANO
Total Studies: 89
Lung Cancer
Criteria: RECIST 1.1/NELSON
Total Studies: 90
Mesothelioma
Criteria: mRECIST Mesothelioma
Total Studies: 7
Cervical Cancer
Criteria: RECIST 1.1
Total Studies: 6
Ovarian / Cervical / Endometrial Cancer
Criteria: RECIST 1.1
Total Studies: 22
Non-Hematological Malignancies, Solid Tumors
Criteria: RECIST 1.1/iRECIST
Total Studies: 73
Breast Cancer
Criteria: RECIST 1.1
Total Studies: 53
Sarcomas
Criteria: RECIST 1.1
Total Studies: 4
Prostate Cancer
Criteria: RECIST 1.1/PCWG3
Total Studies: 23
Renal Cell Carcinoma
Criteria: RECIST 1.1/NELSON
Total Studies: 11

Collect & Hold Solution

Designed for early phase studies:
  • Cost & time savings through prospective collection of study images
  • A secure, centralized location for curated images accelerates drug development timelines when central review is needed
  • MERIT’s image collection leads to improved image quality & reduced variability among various study sites
Program is an annual subscription-based service that consists of:
  • Image collection and quality check, site support
  • Project management services
  • Project start-up documents (abbreviated imaging charter, site survey, site manuals, project plan)
  • MERIT staff to perform image check-in and quality control review
  • Centralized storage & access to view the processed radiologic images on the EXCELSIOR platform
  • Processed images will be DICOM image files that are stored after the Check- with PHI removed

Collect & Hold Case Study

A global, commercial-stage biopharmaceutical company launched a Phase II study with patients at various sites in the US and EU to assess a novel therapeutic agent using PET imaging of solid tumors using RECIST 1.1. MERIT’s Collect & Hold service provided image collection and quality checks, site support, and project management services, as well as quarterly and as needed image transfers, offering the flexibility required for the partially retrospective study.
You have choices for your endpoint services provider.
MERIT values your partnership and will make your study a priority.

TELL US ABOUT
YOUR PROJECT

Connect with us to learn more about how our expertise and approach can support bringing your product to market on-time and on-budget. Your success is our priority.